THBS2 and colorectal carcinoma: As shown Fig. 4B, Kaplan–Meier analysis revealed that the CRC patients with higher level of THBS2 was significantly associated with a poor overall survival (median, 6.54 years) than those with lower level patients (median, 7.77 years, P = 0.018, HR (95% CI) = 2.037(1.118–3.711)).